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ABSTRACT
In resource- constrained environments, priority setting is 
critical to making sustainable decisions for introducing 
new and underused vaccines and choosing among 
vaccine products. Donor organisations and national 
governments in low- income and middle- income countries 
(LMICs) recognise the need to support prioritisation of 
vaccine decisions driven by local health system capacity, 
epidemiology and financial sustainability.
Successful efforts have supported the establishment 
of National Immunisation Technical Advisory Groups 
(NITAGs) to undertake evidence- informed decision making 
(EIDM) in LMICs. Now, attention is increasingly focused 
on supporting their function to leverage local expertise 
and priorities. EIDM and priority- setting functions are 
complex and dynamic processes. Here, we report a pilot 
of a web- based decision- support tool. Applying tenets 
of multicriteria decision analysis, SMART Vaccines 2.0 
supported transparent, reproducible and evidence- 
informed priority setting with an easy- to- use interface and 
shareable outputs.
The pilot was run by the Uganda NITAG who were 
requested by the Ministry of Health (MOH) in 2016 to 
produce recommendations on the prioritised introduction 
of five new vaccines. The tool was acceptable to the NITAG 
and supported their recommendations to the MOH. The 
tool highlighted sensitivity in the prioritisation process 
to the inherent biases of different stakeholders. This 
feature also enabled examination of the implications of 
data uncertainty. Feedback from users identified areas 
where the tool could more explicitly support evidence- to- 
recommendation frameworks, ultimately informing the 
next generation of the platform, PriorityVax.
Country ownership and priority setting in vaccine decisions 
are central to sustainability. PriorityVax promotes auditable 
and rigorous deliberations; enables and captures the 
decision matrix of users; and generates shareable 
documentation of the process.
INTRODUCTION
Twenty years of cofinancing from Gavi, the 
Vaccine Alliance (Gavi) has greatly expanded 
access to underused vaccines and accelerated 
the introduction of vaccines in low- income 
and middle- income countries (LMICs).1 For 
national governments, introducing a new 
or underused vaccine can double or triple 
the cost of routine schedules and addition-
ally commits a country to generations of 
spending.2 As new vaccines and formulations 
become available, the complexity of decision- 
making and resource allocation continue to 
grow. Furthermore, there can be tacit pres-
sure to introduce vaccines,3 both interna-
tional and domestic, to meet health and devel-
opment goals. It is, therefore, unsurprising 
that national- level decision- makers, Gavi and 
other donor organisations seek to ensure 
that existing immunisation programmes are 
sustained while expanding disease prevention 
through new vaccine introduction.
To be eligible for Gavi funding, countries 
must account for a transparent, indepen-
dent evidence- informed process to support 
their applications for financing. Ideally, this 
Summary box
 ► In resource- constrained settings, there is a pressing 
need to support evidence- informed priority setting 
regarding decisions addressing the introduction of 
under- used and new vaccines and to select between 
vaccine products.
 ► The SMART Vaccines 2.0 platform was piloted in 
Uganda where five vaccines were under consider-
ation for inclusion in routine immunisation.
 ► The SMART Vaccines 2.0 tool was found to be 
supportive, and feedback from real- world use has 
streamlined the user experience to avoid onerous 
epidemiological assumptions and data burden.
 ► The most updated version of the tool, PriorityVax, 
fulfils a need to support the deliberative process 
and is especially useful in highlighting the sensitivity 
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process should have three components to promote 
sustainable decisions: an independent body of represen-
tative stakeholders providing advice to the Ministry of 
Health (MOH); the gathering and evaluation of a rele-
vant evidence base; and prioritisation among the options 
considered.
Priority setting is a specialist task4 that extends beyond 
the assessment of evidence because it requires compar-
ison among multiple options across competing interests 
(eg, healthcare specialists, health policy leaders and 
programme and financing decision- makers). Guiding 
frameworks for priority- setting recommend the following 
elements, which are complementary to an evidence- 
informed decision- making (EIDM) process: (1) stake-
holder engagement, (2) use of an explicit process, (3) 
information management, (4) consideration of values and 
context, and (5) revision or appeal mechanism.3 5 System-
atic support for priority setting within National Immuni-
sation Technical Advisory Groups (NITAGs) or MOHs in 
LMICs has been limited.6–9
Substantial efforts to assist LMICs with the identifica-
tion of within- country expertise and the establishment of 
NITAGs10 followed from the first strategic objective of the 
WHO’s Global Vaccine Action Plan 2011–2020.11 These 
independent, expert bodies are expected to review of 
scientific evidence and data representative of the local 
context to inform and develop recommendations to 
support country ownership of policy decisions.12
Supported by Gavi and the Bill and Melinda Gates Foun-
dation, a number of international organisations have 
offered capacity- building support to establish NITAGs. 
While greater emphasis was initially placed on fulfilling 
process indicators for establishing NITAGs, more recent 
efforts have sought to advance functional capabilities asso-
ciated with EIDM, most notably by Agence de Médecine 
Préventive (AMP), the International Vaccine Institute 
and The Sabin Vaccine Institute.13 14 These programmes 
have additionally leveraged technical assistance from 
WHO and its regional offices, PATH and the US Centers 
for Disease Control and Prevention.15 16
These efforts have been important to advancing and 
expanding vaccine coverage in LMICs. Nonetheless, 
both Gavi- eligible countries and those graduating from 
cofunding have reported variable success in sustaining 
immunisation programmes.17 18 Efforts that bring clarity 
to how interventions align with available resources and 
population health priorities are most likely to promote 
the local ownership of decision making that is key to 
sustainable programmes and policies.19–21 Indeed, a 
review of European NITAGs reported that more than half 
the NITAGs (16/27) felt structural differences between 
countries (eg, the role of the NITAG, healthcare systems 
or epidemiological situation) meant recommendations 
would not be applicable elsewhere.22 Consequently, 
although there was support for sharing evaluation of 
evidence, even in middle- income and high- income 
settings there was recognition that recommendations for 
programmes and policies are highly context specific.
In settings where health needs are often unmet and 
health systems are under greater resource constraints, 
enabling locally contextualised, prioritised decision 
making is all the more important. Prioritisation is likely 
to be increasingly relevant to countries that graduate 
from donor support (eg, Gavi) and therefore take on 
the full economic cost of immunisation.18 23 Here, we 
describe the real- world use of a priority- setting tool both 
describing the piloting of the tool and discussing key 
points of the deliberations that arose. The latter will be 
further described elsewhere.
THE CALL FOR PRIORITY SETTING IN UGANDA
In 2016, the Uganda MOH approached its NITAG, which 
was established 2 years earlier, for recommendations on 
which of five available new or reformulated vaccines 
should be introduced into the immunisation schedule: 
meningococcal A, hepatitis B vaccine birth- dose, 
switching from tetanus toxoid to tetanus- diphtheria, 
introducing routine yellow fever vaccine, and a second 
dose of a measles- containing vaccine. Further, the MOH 
was interested in prioritisation among those vaccines 
recommended for introduction.24 The need for prioriti-
sation, rather than simply a go/no- go recommendation, 
was made clear by the challenges facing Uganda’s vacci-
nation portfolio. A projected 90% financing gap (over 
2016–2020) of vaccination programmes when subsidies 
were excluded25 add to challenges of access and delivery 
of vaccines,26 health facility readiness27 and are further 
complicated by Uganda’s refugee population28 and 
porous land borders with countries with endemic and 
zoonotic diseases, for example, meningitis, yellow fever 
and Ebola virus.29–32
Here, we describe the experience of the Uganda NITAG 
(UNITAG) in piloting SMART Vaccines 2.0—a tool to 
support vaccine- related priority- setting decisions—that 
was conducted in parallel with their existing evidence- to- 
recommendation (ETR) framework.
PRIORITY-SETTING FRAMEWORKS
The UNITAG sought technical assistance from AMP’s 
Supporting Independent Vaccine Advisory Committees 
(SIVAC) Initiative,14 and engaged in piloting the SMART 
Vaccines 2.0 platform supported by the Fogarty Inter-
national Center at the US National Institutes of Health 
(NIH). A description of the NITAG process is given else-
where.24 33
SIVAC framework
A number of decision- support tools exist that were either 
built for NITAG use or can be adapted to that purpose. 
However, underlying any tool and the related decision- 
making process are generic skills required to gather and 
interpret evidence. In addition to helping establish and 
strengthen NITAG secretariats, SIVAC produced docu-
mentation and ran workshops to assist with formulating 
evidence- informed recommendations.34 Its framework, 
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used by the UNITAG, was based on WHO practice, using 
the Population, Intervention, Comparator, Outcome 
(PICO) method to formulate precise questions to inform 
systematic literature reviews. This identified evidence 
unique to each vaccine- disease scenario under review. 
The collated evidence was then subjected to an appraisal 
of quality, the UNITAG used a GRADE framework 
(Grading of Recommendations Assessment, Develop-
ment and Evaluation).35
The SIVAC framework was designed to identify, gather 
and evaluate evidence. Its application to prioritisation, 
including a process by which different vaccines could 
be compared against a standard set of decision- making 
criteria, were not part of its intended use. The evaluation 
of each vaccine is considered in isolation. In the case of 
the UNITAG, expert working groups—assigned to each 
of the vaccine- disease combinations—devised PICO 
questions and subquestions unique to each vaccine.
The use of PICO questions to guide a systematic 
review to gather evidence is widely used in, for example, 
Germany,36 Switzerland,37 the UK38 and USA39 where the 
availability of new vaccines means they tend to be consid-
ered individually. These are also settings where resources 
for health investments are much higher than LMICs, for 
example, no benchmark threshold for affordability is used 
by the Swiss Commission Fédérale pour les Vaccinations 
(beyond comparison to existing health interventions)37 
or the US Advisory Committee on Immunisation Prac-
tices39 and the UK broadly follows a figure of £20 000–£30 
000/quality- adjusted life- year.38 The consequence for the 
UNITAG was that the evidence gathered for each of the 
five vaccines under consideration was tailored to the indi-
vidual vaccination PICO questions and not immediately 
comparable between them.
SMART Vaccines 2.0
The SMART Vaccines 2.0 decision- support platform was 
developed using a multi- citeria decision analysis (MCDA) 
framework recommended by the US Institute Of 
Medicine Committee on Identifying and Prioritising New 
Preventive Vaccines for Development that built on earlier 
work stemming from the National Vaccine Plan.7 40 The 
prototype web- based tool was developed at the Fogarty 
International Center at the NIH and the National 
Vaccine Programme Office within the US Department 
of Health and Human Services.6 The tool is designed 
to facilitate and document the deliberative process of 
decision- makers to include the different factors driving 
a decision and their relative weighted importance when 
considering these factors simultaneously among different 
vaccine choices.
The SMART Vaccines 2.0 workflow is illustrated in 
figure 1. Having defined the population, ‘attributes’ or 
criteria considered important for decision making are 
identified. These attributes make explicit the rationale 
for how a vaccine is judged and each criterion is associ-
ated with least to most favourable boundaries that apply 
across each of the vaccines under consideration. In this 
fashion, the evidence for a vaccine is scored relative to 
explicit objectives and is directly comparable. Attributes 
may be qualitative or quantitative and are used to guide 
what information and evidence needs to be collected 
for each vaccine considered in an analysis. Attributes 
themselves are weighted by the decision- makers and this 
process elucidates any predilections. Evidence is then 
input and each vaccine is scored against the attribute 
boundaries. The prioritisation is then the weighted sum 
of the evidence scored for each attribute.
IMPLEMENTATION OF THE DECISION-SUPPORT PROCESS
Establishing decision criteria
Attributes—the decision criteria—in SMART Vaccines 
2.0 were, in this instance, defined to match those of the 
SIVAC framework. When implemented by the UNITAG, 
the SIVAC framework, though adaptable, came prepared 
with four, (implicitly) equally weighted criteria to stim-
ulate discussion in considering the quality of evidence. 
Figure 1 Workflow for SMART Vaccines 2.0. having identified the population (the region and demographic subpopulation), 
attributes are identified that describe the dimensions of the prioritisation and these are weighted to determine the relative 
importance of each attribute. Evidence is collected for each attribute for each vaccine and these, once weighted, are used to 
form a recommendation. GRADE, Grading of Recommendations Assessment, Development and Evaluation.
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Those criteria were (1) the severity of the disease (eg, 
morbidity, mortality and distribution both by age and 
geography), (2) the benefits of the intervention to recip-
ients (including vaccine safety and effectiveness), (3) 
economic consideration (primarily the cost–benefit of 
the vaccine) and (4) programmatic and policy issues (eg, 
how well a vaccine matches the existing EPI, compara-
bility with coadministration and equity).33
Similar processes to support NITAGs often focus initial 
deliberations on the balance between measures of disease 
burden and affordability.41 Recognising the often compli-
cated nature of decision- making, SMART Vaccines 2.0 
was designed to broaden the discussion through presen-
tation of multiple domains following a review of relevant 
stakeholders (figure 2).42 43 These include both quantita-
tive criteria such as the disease burden or cost:benefits, 
and qualitative issues such as meeting policy directives, 
promoting equity (in so far as the vaccine will or not 
address equity or equitable access), or fitting into existing 
immunisation schedules. Whether these domains are 
deemed important to the final recommendation or not, 
it is the discussion triggered by reviewing them that adds 
richness and critical thinking to the deliberations.
Moreover, the SMART Vaccines 2.0 platform offers 
the opportunity to define new criteria unique to the 
decision- makers’ specific circumstances—allowing users 
to tailor the experience to their local needs and choose 
how to capture their priorities, whether they become 
fixed for subsequent recommendations or are reviewed 
each time.22 See figure 3 for a matrix of the key features 
in the platform that align with the priority- setting frame-
work described in the introduction.
Gathering and inputting evidence
The SIVAC framework was populated with evidence that 
was gathered through systematic reviews to address PICO 
questions. Evidence was scored using a GRADE process.35 
This process involved a subjective scale to judge the 
quality of evidence from ‘very low’ to ‘high’ (based on 
the correspondence between the estimate and true effect 
Figure 2 Attributes that can be selected in the SMART Vaccines 2.0 platform that capture the multiple facets of decision 
making regarding the introduction of vaccines. These attributes extend beyond cost–benefits, but equally they are often difficult 
to quantify using empirical evidence, but this should not preclude them from considerations and recommendations. During the 
UNITAG pilot, user- defined attributes were used to match their existing process and these offer greatest flexibility to introduce 
evidence that might account for unique or tailored criteria, but could equally be used to account for alternative specification 
of the same variable (ie, to use external data or a different model to estimate costs/benefits). UNITAG, Uganda National 
Immunisation Technical Advisory Group.
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sizes). For the UNITAG, these text labels were converted 
into a numerical score (0, very low to 4, high) and in 
SMART Vaccines 2.0, attributes were created to mirror 
those of the framework and boundaries were set to reflect 
the GRADE scale (ie, 0–4), although SMART Vaccines 2.0 
can accommodate qualitative or quantitative evidence 
from many sources.
Testing sensitivity
Within SMART Vaccines 2.0, alternative scenarios, for 
example, adjusting the weighting criteria, changing 
the definitions of benchmarked boundary conditions, 
inputting new evidence or exploring the uncertainty 
of existing evidence, can be run quickly. The ability to 
explore the sensitivity of scenarios can contextualise a 
score to provide a better understanding of how uncer-
tainty in inputs, assumptions, or implicit biases might 
influence scoring. This can then help provide credibility 
to discussions that address uncertainty, and can facili-
tate alternative ‘what if…’ scenarios to explore different 
circumstances, for instance, the comparing of funding 
scenarios.
For this pilot, the evidence was considered fixed, but 
using SMART Vaccines 2.0 opened a discussion about the 
relative importance (weights) of the four criteria used 
in the SIVAC framework. The NITAG determined that 
the equal weights of the four attributes implicitly built 
in to the SIVAC framework were not appropriate for the 
Ugandan context. Therefore, to illustrate the diversity 
and robustness of UNITAG considerations, the weights 
given to each criterion were varied in real time. In the 
first instance, the NITAG came to a consensus about 
weights through a Delphi scoring approach, second, each 
member gave weight—separately noting the core (voting) 
and non- core (non- voting) members. Figure 4 illustrates 
the variability in both the weights given by members of 
the NITAG and then the scores of each vaccine scenario. 
The values of each attribute (eg, the severity of disease) 
were fixed across NITAG members as this reflects the 
evidence (agreed on by the Group), whereas the weights 
are subjective and reflect the inherent biases of indi-
vidual NITAG members. It was particularly noteworthy 
that the non- core members, who represented ex officio 
liaison officers from different stakeholders (eg, the WHO 
regional office, UNICEF and the Expanded Immunisa-
tion Programme) tended to be more varied than the core 
members.
Identifying data gaps
The need for comparable data in SMART Vaccines 2.0 
also highlighted gaps in knowledge that were somewhat 
obscured in the SIVAC framework. Because all vaccines 
Figure 4 The weights and scores used by the Uganda 
NITAG in a pilot of the SMART Vaccines prioritisation tool. 
Criteria were selected to match the SIVAC framework and 
scored based on a GRADE- like process. The weight of 
each criterion was then discussed and presented both as 
a consensus (grey squares, showing the mean and ±1 SD) 
of the core (voting) members (blue points) and non- core 
members (yellow points). The weights from each individual 
had to add to 100. The variability in the resultant scores, a 
calculation of weights and scores for the evidence against 
each criterion, is also shown. Despite variability in the 
weights, the prioritisation (rank order) of vaccines remained 
unchanged. it should be noted that these scores formed 
part, but not the whole of the recommendation that was 
contextualised based on the available evidence. GRADE, 
Grading of Recommendations Assessment, Development 
and Evaluation; NITAG; National Immunisation Technical 
Advisory Group; SIVAC, Supporting Independent Vaccine 
Advisory Committee.
Figure 3 Alignment between PriorityVax and parameters 
characterising a successful priority setting framework.
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are compared on the same basis in SMART Vaccines 2.0, 
the data need to be directly comparable, (eg, the type of 
observational data used to measure disease burden needs 
to be the same). In contrast, by treating each recommen-
dation independently, the SIVAC framework permitted 
the use of different data types to satisfy component ques-
tions, (eg, using suspected cases for one disease and lab- 
confirmed diagnoses for another, or whether or not the 
potential for epidemic outbreaks was considered as a 
subcomponent of the disease burden).
LESSONS LEARNT
Acceptability
In a facilitated postmortem, the use of and results from 
SMART Vaccines 2.0 were acceptable to the NITAG. The 
premise satisfied their need to prioritise between vaccines 
and could validate the conclusions drawn through the 
SIVAC process. Reporting and data visualisation outputs 
from SMART Vaccines 2.0 were used to supplement the 
recommendations made to the MOH.33
Limitations
While values were determined by the NITAG, the 
hands- on use was facilitated in- person, including leading 
the NITAG through the interface and discussing the 
consequences of different choices. This worked for a 
pilot by demonstrating the potential of the tool, but it 
did not necessarily demonstrate independent or sustain-
able use of SMART Vaccines 2.0. Three observations 
were made that likely apply to all software during adop-
tion of new tools: (1) there is a learning curve which 
was mollified through facilitation, but in future use it 
remains unclear how ‘standalone’ SMART Vaccines 2.0 
could be, (2) There is a data demand on users. This was 
raised in earlier versions of SMART Vaccines,7 44 however, 
much evidence is specific to vaccines in the local context 
making generic, pre- population of data undesirable. In 
this pilot, SMART Vaccines 2.0 benefited from the data 
collection undertaken to populate the SIVAC framework. 
Generating a similar database is an important and inten-
sive requirement of any ETR process. Ongoing efforts 
to enhance the capacity of NITAGs to independently 
gather, interpret and analyse information will likely 
complement and improve the use of tools like Priori-
tyVax, (3) Advanced users may have their own or existing 
tools. A new tool therefore may find less traction. For 
example, formal health technology assessments (HTA) 
to consider the wider impacts and economics of vaccines 
require specialised skills and are seldom used by under- 
resourced NITAGs,45 but are at the core of others.46 It 
is worth noting that the MCDA framework made acces-
sible through SMART Vaccines 2.0 is increasingly being 
considered to enhance HTA.47
The Evolution of SMART Vaccines 2.0: PriorityVax
Since this pilot of SMART Vaccines 2.0, the tool has 
migrated to the Sabin Vaccine Institute. The platform, 
now named PriorityVax, includes changes to the tool 
based on the experiences with the UNITAG and addi-
tional stakeholder consultation. A major modification 
focused on deemphasising a built- in compartmental 
disease/economic model in order to make the tool more 
generalisable and transparent.
Although the compartmental model was considered a 
highlight of earlier iterations,44 it has become apparent 
that users are either unlikely to have the necessary data 
to run the model (especially across multiple diseases), 
or they will have their own, preferred, models. A generic 
model may appear an attractive option given that devel-
oping such tools requires specialty skills, but it risks 
being inappropriate for any given disease if it cannot 
adequately capture the pertinent disease epidemiology. 
As a consequence, the emphasis is put on employing the 
user- defined attributes to construct appropriate attri-
butes that can be populated with available evidence, for 
example, using a Likert scale to describe the burden of 
disease. This additional flexibility also permits compe-
tition of non- vaccine interventions (eg, screening or 
treatment) within the tools framework, allowing for a 
more holistic consideration of health system constraints 
and benefits. Because MCDA is based on the combi-
nation of weights and values (evidence) both of which 
can be entered by the user rather than generated by the 
disease/economic model, this simplifies the workflow 
considerably (figure 1). That said, some aspects remain 
constrained by the structure of the underlying code.
Simplifying the workflow has also meant that the 
process of using PriorityVax is now clearer and more 
user- friendly. It is envisaged that the updated tool will 
be easier to support remotely if required, including as 
part of ETR training (eg, encouraging exploration of 
sensitivity to bias and data uncertainty). The intention 
is that PriorityVax becomes sufficiently self- explanatory 
such that facilitation is at a minimum or unnecessary, 
thereby giving greater ownership and independence to 
the country- level users and ensuring the sustainability of 
the tool. Gathering and evaluating evidence within an 
ETR framework will always require considerable effort 
and in the interests of time, the UNITAG prioritisation 
process was facilitated by the SMART Vaccine 2.0 team. 
Continued development of supporting ETR guidance 
resources combined with the implementation of the 
tool is envisaged to allow country- level users to make 
their own choices that reflect their unique circumstances 
without the need for externally guided inputs.
The last significant change has been to move the 
modelling code into C#, an accessible and open source 
language. This has improved the stability and perfor-
mance of the website and will permit easier implementa-
tion of future updates.
CONCLUSIONS
In resource- constrained settings, prioritising among 
new and underused vaccination strategies or selecting 
between vaccine products, will support long- term 
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commitment and sustained investments. A local decision 
of which or whether, to introduce a vaccine is a funda-
mental component of developing evidence- informed 
recommendations given the expanding range of vaccines 
available and increasing costs implied. PriorityVax (the 
successor to SMART Vaccines 2.0) is a platform designed 
to capture deliberations around prioritisation, to explic-
itly evidence the importance of different criteria and 
produce a consistent documented process that supports 
transparent EIDM.48 In the piloted implementation, 
the platform’s value was demonstrated by its acceptance 
among the users to support a real- world priority- setting 
process.
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